Post-treatment Surveillance in HPV+ Oropharyngeal SCC
In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
- Oropharyngeal Squamous Cell Carcinoma
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Participants must have histologically or cytologically confirmed incident or recurrent squamous cell carcinoma of the tonsil or base of tongue (oropharynx) - includes biopsy of any lymph node with clinical evidence of an oropharynx tumor (unknown primary carcinoma in an involved cervical neck lymph node is permitted if high-risk HPV testing is positive on the involved node) - HPV-associated tumor as defined by one or more : positive p16 immunohistochemistry (>70%) OR in situ hybridization OR PCR-based methods - Age 18 years or older - Will undergo oropharyngeal cancer treatment with curative intent - Ability to understand and the willingness to sign a written informed consent document. - Baseline positive or detectable ctHPV DNA result prior to treatment
- Distant metastatic disease (M1, AJCC 8th edition) - Undetectable ctHPV DNA result at baseline
- Study Type
- Observational Model
- Time Perspective
|HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients||Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) patients will undergo blood testing for circulating tumor HPV DNA.||
- Dana-Farber Cancer Institute
Study ContactEleni M Rettig, MD
This research study involves blood tests to detect HPV DNA at regular time points after treatment for HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC). Participants may undergo scans based on the results of the blood tests. Study participants will also be asked to complete quality of life questionnaires periodically. Participation in this study may last for up to 5 years. It is expected that about 150 people will take part in this research study.